Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DECIDE-MET: MET inhibitors versus immune checkpoint inhibitor-based therapy in advanced NSCLC with MET exon 14 skipping
jRCT1031260225Phase 3Recruiting
- Sponsor
- Japan Clinical Oncology Group
- Start
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of tepotinib, capmatinib and pembrolizumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Japan Clinical Oncology Group. Primary endpoint: overall survival. Started Jun 2026; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT1031260225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031260225.